Eric Edidin

Eric Edidin is a highly accomplished professional with an extensive background in finance, biotechnology, and investment management.

He holds a Master of Business Administration (MBA) from Harvard Business School and a Bachelor's degree in Finance and Accounting from the University of Michigan.

Currently serving as the Executive Chairman at BH3 Management, Eric has held key leadership positions in various organizations, showcasing his strategic acumen and business leadership skills.

His previous roles include Chairman of the Board at Crixus BH3 Acquisition Company, as well as board positions at ILiAD Biotechnologies, LLC, Diasome Pharmaceuticals, Inc., GVNG, Cecelia Health, Mellitus Health, and Spartacus Acquisition Corporation.

Eric Edidin has a rich history in investment management, having founded Endo Investors, served as Co-Founder & Co-Managing Partner at Archer Capital Management, and held the role of Portfolio Manager / Co-Head Credit at York Capital Management.

His solid financial expertise was honed through his experience as an Associate at Morgan Stanley and The Blackstone Group, further solidifying his reputation in the financial sector.